|ALK-1 (for heme cases)The ALK1 (ALK1 cline) antibody labels normal human ALK protein and the NPM-ALK chimeric protein, and is a useful tool for the identification of the subgroup of anaplastic large-cell lymphomas (ALCL) that are ALK positive.||Immunohistochemistry (IHC)|
|B-Cell Gene Rearrangement
Detection of clonal IgH gene rearragements by PCR of IgH framework regions 1, 2, 3 and joining regions. In addition, Ig Kappa gene rearrangement analysis is performed using specific oligonucleotides recognizing the Vk, intragenic and Jk regions. Testing is approved for specimens from the state of New York.
|BOB1BOB1 is present in all B-cells expressing Ig. The combination of BOB1 and OCT2 staining is helpful in distinguishing between classical Hodgkin lymphoma (at least one marker negative) and nodular lymphocyte predominant Hodgkin lymphoma or T-cell histiocyte-rich large B-cell lymphoma (both markers expressed).||Immunohistochemistry (IHC)|
|CD15CD15 (X-Hapten) plays a role in mediating phagocytosis, bactericidal activity, and chemotaxis. It is present on granulocytes, including neutrophils and eosinophils, and to a lesser degree on monocytes. CD15 is also expressed in Reed-Sternberg cells and some epithelial cells. CD15 antibody is useful in the identification of Hodgkin lymphoma. CD15 is occasionally expressed in large cell lymphomas of both B- and T- phenotypes.||Immunohistochemistry (IHC)|
|CD20Normal cell expression of CD20 is found on most B-cells (after CD19 and CD10 expression, before CD21/22 expression and surface immunoglobulin expression) and expression is retained on mature B-cells until plasma cell development, as well as ollicular dendritic cells. In diseased cells, there is positive staining on most B-cell lymphomas, come pre-acute B lymphoblastic leukemia/ lymphoblastic lymphoma (B-ALL/LBL); lymphocyte predominant Hodgkin lymphoma, dimly expressed in T-cells (benign and neoplastic), and spindle cell thymomas. Rixtuximab treated patients may lose CD20 positivity in B cell lymphomas.||Immunohistochemistry (IHC)|
|CD3The CD3 antigen is first detectable in early thymocytes and its appearance probably represents one of the earliest signs of commitment to the T-cell lineage. It has a cytoplasmic expression at early T-cell differentiation, then membranous expression. CD3 is the most specific T-cell antibody. CD3 is expressed in normal thymocytes, peripheral T-cells, NK cells, and Purkinje cells of cerebellum. In diseased cells, CD3 stains most T-cell lymphomas. Only rare B cell lymphomas may be positive for CD3.||Immunohistochemistry (IHC)|
|CD30CD30 is a lymphocyte activation antigen, related to tumor necrosis factor. It is expressed in activated B-, T- and NK cells. Positive staining is seen in infectious mononucleosis, lymphocytes infected with HIV, HTLV-1, EBV, HHV8 or hepatitis B, Reed-Sternberg cells, anaplastic large cell lymphomas (90%), lymphomatoid papulosis, peripheral T-cell lymphomas, and embryonal cell tumors.||Immunohistochemistry (IHC)|
|CD45 (LCA)CD45 (Leukocyte Common Antigen, LCA) is comprised of at least four isoforms (CD45RA, CD45RB, CD45RC and CD45RO) of membrane glycoproteins. CD45 is expressed on hematopoietic cells (human leukocytes, including lymphocytes, monocytes, and eosinophils), but is absent on normal and malignant non-hematopoietic tissues.||Immunohistochemistry (IHC)|
|CD79aCD79a first appears at the pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B-cell type, B-cell lines, B-cell lymphomas, and in some myelomas. It is not present in myeloid cells or T-cells.||Immunohistochemistry (IHC)|
This probe set labels all latent EBV-infected cells, including EBV-positive lymphoblastoid cell lines and EBV infected B-cell immunoblasts in infectious mononucleosis. It also reacts with EBV-associated undifferentiated nasopharyngeal carcinomas and with Reed-Sternberg cells in almost all EBV-associated Hodgkin lymphoma cases. Global interpretation is available on head and neck specimens only; tech-only testing is available for all samples.
|In Situ Hybridization (ISH)|
|FascinHuman fascin is a highly conserved actin-bundling protein. It is expressed predominantly in dendritic cells. Lymphoid cells, myeloid cells and plasma cells are negative for staining. However, Reed-Sternberg cells in Hodgkin lymphoma are positive for fascin staining. Epstein-Barr virus may induce expression of fascin in B-cells.||Immunohistochemistry (IHC)|
Ki67 is a nuclear protein that is expressed in proliferating cells. Ki67 is preferentially expressed during late G1, S, M, and G2 phases of the cell cycle, while cells in the G0 (quiescent) phase are negative for this protein. Increased proliferative activity is associated with more aggressive tumor and decreased disease-free survival period.
|OCT2Octamer Binding Transcription Factor 2 (OCT2) is present in all B-cells expressing Ig. The combination of BOB1 and OCT2 stains is helpful in distinguishing between classical Hodgkin lymphoma (at least one marker negative) and nodular lymphocyte predominant Hodgkin lymphoma (both markers expressed). Classical Hodgkin lymphoma stains as BOB1-OCT2+ or BOB1+ OCT2-, while nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) or diffuse large B-cell lymphoma (DLBCL) stains BOB1+ OCT2+.||Immunohistochemistry (IHC)|
|PAX5Paired Box 5 (PAX5) is a B-cell specific activator protein (BSAP). In early stages of B-cell development, PAX5 influences the expression of several B-cell specific genes, such as CD19 and CD20. PAX5 is expressed primarily in pro-, pre-, and mature B-cells, but not in plasma cells. There is an excellent correlation between CD20 and PAX5 expression; however, anti-PAX5 exceeds the specificity and sensitivity of L26 (CD20) because of its earlier expression in B-cell differentiation and its ability to detect all committed B-cells, including classic Hodgkin lymphoma. It is very specific to B-cell lineage and does not stain T-cells.||Immunohistochemistry (IHC)|
|Standard Leukemia/Lymphoma Panel - 24 markers
Available as global and tech-only. Markers are CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD13, CD14, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD45, CD56, CD64, CD117, HLA-DR, kappa, and lambda.
|T-Cell Receptor Beta Gene Rearrangement
This test provides qualitative detection of monoclonal T-cell receptor (TCR) beta gene rearrangements by PCR and fragment analysis according to BIOMED-2 consensus primer design. This test may be ordered concurrently with or after negative results in our T-Cell Receptor Gamma Gene Rearrangement assay for gamma gene rearrangements to improve TCR rearrangement detection by ~5% in T-cell leukemias/lymphomas.
|T-Cell Receptor Gamma Gene Rearrangement
Detection of clonal T-cell receptor gamma (TCRG) gene rearrangements by PCR of variable and joining regions. T-Cell Receptor Beta Gene Rearrangement is offered separately and may be added to this gamma gene test.
|Universal Fusion/Expression Profile
The Universal Fusion/Expression Profile is a targeted RNA sequencing panel that utilizes next-generation sequencing (NGS) to detect all relevant fusion transcripts in 1,385 genes associated with hematologic or solid tumor cancers. It is especially useful for testing patients with rare diseases. Learn more about the Universal Fusion/Expression Profile. See the full 1,385 gene list here.
|Wright GiemsaCytochemical stain. The Wright Giemsa stain is used to stain peripheral blood and bone marrow smears for study of blood cell morphology.||Immunohistochemistry (IHC)|
Displaying 1 - 19 of 19 tests